Haemonetics (HAE)
(Delayed Data from NYSE)
$87.66 USD
+1.44 (1.67%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $87.59 -0.07 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Company Summary
Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company’s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. Blood and its components (plasma, platelets, and red cells) have several vital and frequently life-saving clinical applications.
On Aug 1, 2012, Haemonetics acquired Pall Corporation’s blood collection, filtration and processing product lines. Haemonetics entered into a long-term supply agreement with Pall in May 2018, ...
Company Summary
Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company’s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. Blood and its components (plasma, platelets, and red cells) have several vital and frequently life-saving clinical applications.
On Aug 1, 2012, Haemonetics acquired Pall Corporation’s blood collection, filtration and processing product lines. Haemonetics entered into a long-term supply agreement with Pall in May 2018, under which Pall will continue to supply media to Haemonetics for use in leukoreduction filters. As a condition of the supply agreement, Haemonetics agreed to accept the HDC line and make a final payment of $9 million to Pall for the same.
Further, in May 2013, the company acquired Hemerus Medical, a Minnesota-based company that develops innovative technologies for the collection of whole blood and processing and storage of blood components, including SOLX storage solutions.
Earlier, the company reported its operating results in 4 business franchises: Plasma, Hemostasis Management, Cell Processing and Blood Center. However, as the annual report released in May 2019, the reporting segments for the company’s products have been reduced to three, namely, Plasma, Blood Center, and Hospital.
Plasma (42.5% of revenues in fiscal 2023, up 41.4% from fiscal 2022) includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers.
Blood Center (23.9%, down 6.2%) includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software.
Hospital (31.8%, up 15.2%) includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.
General Information
Haemonetics Corporation
125 Summer Street
Boston, MA 02110
Phone: 781-848-7100
Fax: 781-848-5106
Web: http://www.haemonetics.com
Email: olga.guyette@haemonetics.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | March |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/9/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.88 |
Current Year EPS Consensus Estimate | 3.95 |
Estimated Long-Term EPS Growth Rate | 10.00 |
Earnings Date | 5/9/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 86.22 |
52 Week High | 95.26 |
52 Week Low | 70.74 |
Beta | 0.36 |
20 Day Moving Average | 401,079.81 |
Target Price Consensus | 105.80 |
4 Week | 2.53 |
12 Week | 12.77 |
YTD | 0.83 |
4 Week | 6.11 |
12 Week | 7.74 |
YTD | -5.17 |
Shares Outstanding (millions) | 50.79 |
Market Capitalization (millions) | 4,378.78 |
Short Ratio | NA |
Last Split Date | 12/3/2012 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 20.35 |
Trailing 12 Months | 22.40 |
PEG Ratio | 2.04 |
vs. Previous Year | 22.35% |
vs. Previous Quarter | 5.05% |
vs. Previous Year | 10.14% |
vs. Previous Quarter | 5.68% |
Price/Book | 4.64 |
Price/Cash Flow | 17.33 |
Price / Sales | 3.45 |
3/31/24 | NA |
12/31/23 | 22.37 |
9/30/23 | 22.33 |
3/31/24 | NA |
12/31/23 | 9.71 |
9/30/23 | 9.61 |
3/31/24 | NA |
12/31/23 | 2.92 |
9/30/23 | 3.28 |
3/31/24 | NA |
12/31/23 | 1.76 |
9/30/23 | 2.19 |
3/31/24 | NA |
12/31/23 | 15.50 |
9/30/23 | 15.10 |
3/31/24 | NA |
12/31/23 | 9.97 |
9/30/23 | 10.35 |
3/31/24 | NA |
12/31/23 | 12.68 |
9/30/23 | 12.85 |
3/31/24 | NA |
12/31/23 | 18.59 |
9/30/23 | 17.62 |
3/31/24 | NA |
12/31/23 | 2.10 |
9/30/23 | 2.15 |
3/31/24 | NA |
12/31/23 | 0.91 |
9/30/23 | 0.84 |
3/31/24 | NA |
12/31/23 | 47.60 |
9/30/23 | 45.59 |